(Q38013786)

English

Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model

scientific article published on July 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

0 references

Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

0 references

rheumatoid arthritis

0 references

0 references

author name string

Christine M Nguyen

1

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Mark Bounthavong

2

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Margaret A S Mendes

3

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Melissa L D Christopher

4

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Josephine N Tran

5

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Rashid Kazerooni

6

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Anthony P Morreale

7

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

publication date

1 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

575-593

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Guidelines for the management of rheumatoid arthritis: 2002 Update

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Markov models in medical decision making: a practical guide.

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Bayesian methods for evidence synthesis in cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Methods in health service research. An introduction to bayesian methods in health technology assessment

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS.

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Bayesian approaches to random-effects meta-analysis: a comparative study.

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Inference from Iterative Simulation Using Multiple Sequences

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Handling uncertainty in cost-effectiveness models

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Representing uncertainty: the role of cost-effectiveness acceptability curves

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Cost-effectiveness of seven IVF strategies: results of a Markov decision-analytic model.

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI).

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Critical appraisal of pharmacoeconomic studies comparing TNF-alpha antagonists for rheumatoid arthritis treatment

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Societal cost of rheumatoid arthritis patients in the US.

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

Biologic drugs for rheumatoid arthritis in the medicare program: A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.2165%2F11594990-000000000-00000

21 January 2018

What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22640174

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st

1 reference

https://pubmed.ncbi.nlm.nih.gov/22640174

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ACR 20: clinical or statistical significance?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22640174

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Update: direct and indirect costs of arthritis and other rheumatic conditions--United States, 1997.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22640174

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Deaths: final data for 2003.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22640174

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22640174

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22640174

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measuring preference weights for American college of rheumatology response criteria for patients with rheumatoid arthritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22640174

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnosis and management of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22640174

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22640174

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22640174

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Magnitude and characteristics of arthritis and other rheumatic conditions on ambulatory medical care visits, United States, 1997

1 reference

https://pubmed.ncbi.nlm.nih.gov/22640174

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11594990-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38013786&oldid=2201172306"